Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26256957 | 0.91 | AAK1 (0.33) | GRM2AAK1ESR1KCNH2SLC7A5 | |
| SCHEMBL6677666 | 0.87 | ESR1 (0.42) | GRM2AAK1HDAC3HDAC1HDAC2 | |
| SCHEMBL1626936 | 0.87 | TSHR (0.40) | GRM2HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL6678068 | 0.85 | REN (0.36) | GRM2AAK1HDAC3HDAC1HDAC2 | |
| SCHEMBL6677867 | 0.84 | KDM4E (0.36) | GRM2L3MBTL1TSHRALDH1A1HSD17B10 | |
| SCHEMBL7872408 | 0.82 | HDAC1 (0.34) | GRM2HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL7880189 | 0.81 | AAK1 (0.34) | GRM2AAK1ESR1KCNH2SLC7A5 | |
| SCHEMBL13656744 | 0.81 | NR1D1 (0.40) | GRM2HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL7880112 | 0.80 | HDAC3 (0.33) | GRM2HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL12569696 | 0.79 | PRKCI (0.38) | GRM2AAK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4493546-B1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-4493546-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2025-01-22 | — | — | EP | disclosed |
| US-12030856-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2024-07-09 | — | — | US | disclosed |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-12-14 | — | — | US | disclosed |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-12-14 | — | — | US | disclosed |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-12-14 | — | — | US | disclosed |
| WO-2023174836-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023174836-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-09-21 | — | — | WO | disclosed |
| EP-4245753-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2023-09-20 | — | — | EP | disclosed |
| EP-4245753-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2023-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030856-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | GRM2 2296/4885AAK1 1034/4885HDAC3 349/4885 |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | GRM2 2400/4885AAK1 722/4885HDAC3 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.